Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
用户iqhGP5oH2vOo
26天前
51
10
已完结
1. 系统已在2025-09-15 18:17:46对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S1470-2045(24)00673-9
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204524006739
其他信息:
出版社: Elsevier BV
作者: Hope S Rugo; Florence Lerebours; Eva Ciruelos; Pamela Drullinsky; Manuel Ruiz-Borrego; Patrick Neven; Yeon Hee Park; Aleix Prat; Thomas Bachelot; Dejan Juric; Nicholas Turner; Nickolas Sophos; Juan Pablo Zarate; Christina Arce; Yu-Ming Shen; Stuart Turner; Hemanth Kanakamedala; Wei-Chun Hsu; Stephen Chia
